Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201105438 Principal Investigator: Linette, Gerald
Title: A phase II, open label, multi-center, single-arm study to assess the efficacy of Tasigna® in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation
Phase: II Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
This trial is being carried out to compare the efficacy and safety of nilotinib to the drug dacarbazine in patients with c-Kit mutated metastatic and/or inoperable acral, mucosal or chronic sun-damaged melanoma.

Patients in this study will be treated with either nilotinib or DTIC.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)